Future costs in cost effectiveness analysis.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Health Economics

• Publication date

  2008-07-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1016/j.jhealeco.2007.09.011PMID 18201785
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden

  2012cited by this paper
• Cost-Effectiveness of Coronary Artery Bypass Grafts Versus Percutaneous Coronary Intervention for Revascularization of High-Risk Patients

  2006cited by this paper
• Defining the value of a statistical life: a comment.

  2002cited by this paper
• The cost‐effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub‐study to the HOPE study

  2002cited by this paper
• Is there a meaningful definition of the value of a statistical life?

  2001cited by this paper
• Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus.

  2000cited by this paper
• Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study.

  2000cited by this paper
• Incorporating Future Costs in Medical Cost-Effectiveness Analysis

  1997cited by this paper
• Theoretical issues in cost-effectiveness analysis.

  1997cited by this paper
• Intergenerational equity: an exploration of the 'fair innings' argument.

  1997cited by this paper
• Economic foundations of cost-effectiveness analysis.

  1997cited by this paper
• Accounting for future costs in medical cost-effectiveness analysis.

  1997cited by this paper
• Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

  1996cited by this paper
• Change in expenditure patterns of retirees: 1972-1973 and 1986-1987.

  1995cited by this paper
• Cost-effectiveness of the treatment of hypertension.

  1993cited by this paper
• Is screening for breast cancer cost‐effective?

  1992cited by this paper
• Earnings Uncertainty and Aggregate Wealth Accumulation

  1991influential reference
• Is Prevention Better Than Cure

  1987influential reference
• Is Prevention Better Than Cure?

  1986cited by this paper
• Capital Accumulation and Uncertain Lifetimes with Adverse Selection

  1985influential reference
• On Uncertain Lifetimes

  1977cited by this paper

• The impact of different perspectives on the cost-effectiveness of remote patient monitoring for patients with heart failure in different European countries

  2024cites this paper
• Incorporating future unrelated medical costs in cost-effectiveness analysis in China

  2021cites this paper
• Estimating the costs of non-medical consumption in life-years gained for economic evaluations.

  2021cites this paper
• Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies.

  2021cites this paper
• Catalog of Age- and Medical Condition-Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis.

  2021cites this paper
• Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health andMedicine

  2020cites this paper
• Replication studies in economics—How many and which papers are chosen for replication, and why?

  2019cites this paper
• Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients

  2019cites this paper
• Family Planning and HIV Interventions among Women in Low-income Settings

  2018cites this paper
• Future Costs in Cost-Effectiveness Analyses: Past, Present, Future

  2018cites this paper
• Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary

  2018cites this paper
• Screening and brief intervention for obesity in primary care: cost-effectiveness analysis in the BWeL trial

  2018cites this paper
• Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan.

  2017cites this paper
• The purgatorial shadows of war: Accounting, blame and shell shock pensions, 1914–1923

  2017cites this paper
• Unrelated future costs and unrelated future benefits: Reflections on NICE Guidance to the Methods of Technology Appraisal Keywords: health technology assessment, economic analysis, cost effectiveness analysis, costing, unrelated future costs

  2016cites this paper
• Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.

  2016cites this paper
• Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.

  2016cites this paper
• Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis.

  2016cites this paper
• Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis

  2015cites this paper
• Incorporation of future costs in health economic analysis publications: current situation and recommendations for the future

  2015cites this paper
• Pertussis Post-Exposure Prophylaxis among Household Contacts: A Cost-Utility Analysis

  2015cites this paper
• The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology

  2015cites this paper
• Modelling the Logistics Response to a General Infectious Disease

  2015cites this paper
• Ethical Objections Against Including Life-Extension Costs in Cost-Effectiveness Analysis: A Consistent Approach

  2014cites this paper
• Assessing Technologies That Are Not Cost-Effective at a Zero Price

  2014cites this paper
• Health care expenditures from living longer--how much do they matter.

  2014cites this paper
• Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.

  2013cites this paper
• Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.

  2013cites this paper
• Apples and oranges: a comparison of costing methods for obesity

  2013cites this paper
• Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis

  2012cites this paper
• Simplifying rules for optimal allocation of preventive care resources

  2012cites this paper
• Technology growth and expenditure growth in health care.

  2012cites this paper
• Cost–effectiveness of preventing weight gain and obesity: what we know and what we need to know

  2012cites this paper
• The evaluation of lifestyle interventions in the Netherlands

  2012cites this paper
• Kostenmessung bei Krankheiten mit Langzeitüberleben

  2012cites this paper
• 2. How to Handle with ^|^quot;Unrelated Cost^|^quot; in Economic Evaluation?

  2012cites this paper
• Role of CCR5 in the cardiovascular complications of renal disease and diabetes

  2012cites this paper
• The value of personalized approaches to improve pharmacotherapy in renal disease

  2012cites this paper
• Describing, explaining and predicting health care expenditures with statistical methods

  2012cites this paper
• Tipos de Cos Tes a in Cluir en una evalua Ción eConómi Ca

  2012cites this paper
• Tipos de costes a incluir en una evaluación económica

  2012cites this paper
• Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.

  2012cites this paper
• Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients

  2011cites this paper
• Health and economic burden of the projected obesity trends in the USA and the UK.

  2011cites this paper
• Gesundheitsökonomische Methoden in der Prävention

  2011cites this paper
• Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis.

  2011influential citation
• University of Groningen Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis Vegter,

  2011cites this paper
• Economic evaluation and the postponement of health care costs.

  2011influential citation
• University of Groningen ECONOMIC EVALUATION AND THE POSTPONEMENT OF HEALTH CARE COSTS

  2011cites this paper
• Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations

  2011cites this paper
• Revealing age-specific past and future unrelated costs of pneumococcal infections by flexible generalized estimating equations

  2011cites this paper
• Incentives for Optimal Allocation of HIV Prevention Resources

  2010cites this paper
• Economische evaluaties en de zorgkosten van levensverlenging

  2010cites this paper
• On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected

  2010cites this paper
• WHO Guide for standardisation of economic evaluations of immunization programmes.

  2010cites this paper
• OR's Next Top Model: Decision Models for Infectious Disease Control

  2009cites this paper
• I costi sanitari indiretti (non correlati) durante gli anni di vita guadagnati

  2009cites this paper
• Incorporación de los costes futuros en los análisis farmacoeconómicos: principios y práctica

  2008cites this paper
• Thinking rigorously about future costs in cost effectiveness analysis

  2008cites this paper
• Future costs in economic evaluation. A comment on Lee.

  2008cites this paper
• Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

  2008cites this paper
• Unrelated Medical Costs in Life-Years Gained

  2008cites this paper